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Abstract:
Background:
Aerococcus urinae and Aerococcus sanguinicola are relatively newcomers and emerging organisms in clinical and microbiological
practice. Both species have worldwide been associated with urinary tract infections. More rarely cases of bacteremia/septicemia and
infective endocarditis have been reported. Treatment options are therefore important. Just recently, European recommendations on
susceptibility testing and interpretive criteria have been released.
Objective:
In this investigation 120 A. urinae and A. sanguinicola isolates were tested for susceptibility to six antimicrobial agents: Penicillin,
cefotaxime, meropenem, vancomycin, linezolid, and rifampicin.
Methods:
Three susceptibility testing methods were used; disk diffusion according to The European Committee on Antimicrobial Susceptibility
Testing (EUCAST) standardized disk diffusion methodology and MIC determination with Etest and broth microdilution (BMD). All
testing was performed with EUCAST media for fastidious organisms.
Results:
Data obtained in this study were part of the background data for establishing EUCAST breakpoints. MIC values obtained by Etest
and BMD were well correlated with disk diffusion results.
*  Address  correspondence  to  this  author  at  the  Department  of  Clinical  Microbiology,  Slagelse  Hospital,  Ingemannsvej  46,  DK-4200  Slagelse,
Denmark; Tel: (+45)58559404; Fax: (+45)58559410; E-mail: jejc@regionsjaelland.dk
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Conclusion:
All isolates were found susceptible to all six antimicrobial agents: penicillin, cefotaxime, meropenem, vancomycin, linezolid, and
rifampicin.
Keywords:  Aerococcus  urinae,  Aerococcus  sanguinicola,  Antimicrobial  susceptibility  testing,  Urinary  tract  infections,  Disk
diffusion,  Etest,  Broth  microdilution.
1. INTRODUCTION
During the past one to two decades, the clinical relevance of various catalase-negative, Gram-positive cocci has
been increasingly pointed out. Among these, Aerococcus urinae and Aerococcus sanguinicola are relatively newcomers
and emerging organisms in clinical and microbiological practice [1 - 3]. Both species have worldwide been associated
with urinary tract infections especially in elderly predisposed patients. A prevalence of A. urinae isolates in up to 4% of
urine  specimens  examined  has  been  reported  [4].  Both  species  have  also  been  isolated  from  blood  from  patients
suffering from urogenic bacteremia/septicemia, in few cases with complicating infective endocarditis. Isolates of both
species have furthermore casuistically been isolated from other foci too [1].
Isolates  from  both  species  are  characterized  by  Staphylococcus-like  morphology  in  Gram  stains  with  growth
characteristics  resembling α-hemolytic  streptococci  on blood containing agar  plates,  a  negative  catalase  reaction,  a
consistent  antibiogram demonstrating  susceptibility  to  β-lactams,  and  for  A.  urinae  resistance  to  sulfonamides  and
aminoglycosides [5]. Recognition of the species may be harmed by their fastidious growth, which not seldom require
supplementation with CO2 for optimal growth [5]. Diagnosing infections caused by both organisms are still missed in
many laboratories around the world. However, with the increasing use of MALDI-TOF mass spectrometry for species
identification, both species are diagnosed with increasing frequency [6].
Data on in vitro susceptibility of A. urinae isolates are accumulating [3, 4, 7 - 10]. The number of susceptibility
reports on A. sanguinicola are relatively sparse compared to A. urinae [7, 11 - 14]. A lack of standardized susceptibility
test methods and interpretive criteria for Aerococcus spp. have been problematic for clinical laboratories and clinicians
[9].  Most  publications  have  used  the  interpretive  criteria  for  viridans  group  streptococci  when  evaluating  the
susceptibility.  In  general,  both  species  exhibit  susceptibility  to  penicillin  and  vancomycin  and  low level  resistance
towards aminoglycosides [10]. A. urinae is susceptible to nitrofurantoin [13].
A variety of test methods have been reported, and interpretive criteria for streptococci,  staphylococci,  and even
enterococci  have  been  applied  [9].  In  order  to  obtain  comparable  results  it  is  desirable  to  develop  a  standardized
methodology and interpretation when performing susceptibility testing on especially these two Aerococcus species. In
the last revision from August 2016 of the US guideline from the Clinical and Laboratory Standards Institute (CLSI) on
“Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria” (M45)
[15] a table on aerococci has been included.
In this study, 120 aerococcal isolates, A. urinae (n = 81) and A. sanguinicola (n = 39), of European origin were
tested for susceptibility to six antimicrobial agents using the methodology recommended by The European Committee
on  Antimicrobial  Susceptibility  Testing  (EUCAST).  Data  obtained  in  this  study  acted  as  part  of  the  decision
background  for  creating  European  clinical  breakpoints  for  A.  urinae  and  A.  sanguinicola  [16].
2. MATERIALS AND METHODS
2.1. Isolates
Eighty-one isolates of A. urinae and 39 isolates of A. sanguinicola of European origin were examined. Of the 81
isolates  of  A.  urinae,  58  were  from urine,  22  from blood,  and  one  foot  wound  isolate;  41  isolates  originated  from
Switzerland, 37 isolates from Denmark and two isolates from Spain. Of the 39 isolates of A. sanguinicola, 37 were from
urine and 2 from blood; 29 isolates originated from Switzerland, 8 isolates from Denmark and one isolate from Spain.
Two type strains were also included: A. urinae CCUG 36881T and A. sanguinicola CCUG 43001T. All isolates were
species identified using MALDI-TOF mass spectrometry (Bruker Daltonics, Germany).
2.2. Susceptibility Testing
Three antimicrobial susceptibility testing methods were used; disk diffusion according to EUCAST standardized
disk diffusion methodology for fastidious organisms [17] and MIC determination using Etest (bioMérieux, France) and
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broth microdilution (BMD) according to ISO standard 20776-1 [18] using Thermo Scientific Sensititre panels (East
Grinstead,  UK).  The  following  six  antimicrobial  agents  were  tested:  Benzylpenicillin,  cefotaxime,  meropenem,
vancomycin, linezolid, and rifampicin. Rifampicin was not included in the BMD panel, therefore only tested with disk
diffusion and Etest. The following disks (Oxoid, UK) was used: Benzylpenicillin 1 unit, cefotaxime 5 µg, meropenem
10 µg, vancomycin 5 µg, linezolid 10 µg, and rifampicin 5 µg. The following Etest strips were used: Benzylpenicillin
0.002-32  mg/L,  cefotaxime  0.016-256  mg/L,  meropenem  0.002-32  mg/L,  vancomycin  0.016-256  mg/L,  linezolid
0.016-256 mg/L, and rifampicin 0.002-32 mg/L. BMD (Sensititre): Benzylpenicillin 0.03-4 mg/L, cefotaxime 0.12-4
mg/L, meropenem 0.25-2 mg/L, vancomycin 0.5-1 mg/L, and linezolid 0.25-4 mg/L.
For disk diffusion and Etest, preparation of inocula, inoculation and incubation of plates were performed according
to EUCAST disk diffusion methodology using a McFarland 0.5 inoculum on Mueller-Hinton (MH) agar plates with 5%
defibrinated horse blood and 20 mg/L β-NAD (MH-F plates) and incubation at 35 °C in 5% CO2 for 16-20 hours. If
poor growth was observed after 16-20 h incubation, isolates were re-incubated and inhibition zones and MICs read after
a total of 40-44 h incubation. Zone edges were read as the point showing no growth viewed with the naked eye from the
front  of  the  plate  with  the  lid  removed  and  with  reflected  light.  BMD (Sensititre)  was  performed  using  a  5  x  105
CFU/mL inoculum prepared in MH-F broth [19] added to Sensititre STP6F BMD plates and sealed before incubation at
35 °C in ambient air for 16-20 h before reading. As for disk diffusion and Etest, the BMD plates were re-incubated and
read after a total of 40-44 h if growth was poor after 16-20 h incubation.
Simultaneous  with  the  clinical  isolates,  the  QC  strain  Streptococcus  pneumoniae  ATCC  49619  was  tested  for
susceptibility to the six examined antimicrobial agents using the three susceptibility testing methods.
3. RESULTS
On MH-F agar, confluent lawn of growth was observed after 16-20 h incubation for A. urinae and A. sanguinicola
isolates. By disk diffusion, Etest, and BMD determinations, 14 of the A. urinae isolates had weak growth after 16-20 h
incubation and needed prolonged incubation (40-44 h).
Antimicrobial susceptibility test results (disk diffusion zone diameters, MIC50, MIC90, and MIC ranges) with the
three  used  methods  are  given  in  (Tables  1  and  2),  for  A.  urinae  and  A.  sanguinicola  isolates,  respectively.  Zone
histograms of disk diffusion against corresponding BMD MICs are visualized using different colors for each MIC in the
supplementary  material.  Normal  MIC  distributions  were  obtained  for  both  methods  (data  not  shown).  Using  the
EUCAST recommendations, Etest and BMD MIC values were obtained for 76-81 A. urinae strains and for 38-39 A.
sanguinicola strains.
Table 1. MICs and zone diameters for A. urinae isolates when tested by EUCAST standardized disk diffusion method, Etest,
and broth microdilution (Sensititre).
A. urinae
Disk diffusion
(wildtype)
Etest Broth microdilution *
No. of isolates with MIC (mg/L) MIC (mg/L) MIC (mg/L)
Antibiotic mm <0.002 0.004 0.008 0.016 0.032 0.064 0.125 0.25 0.5 1 2 MIC50 MIC90 Range MIC50 MIC90 Range
Benzylpenicillin 29-40 8 31 28 10 1 0.032 0.064 0.008-0.125 ≤0.03 0.06 ≤0.03-0.06
Cefotaxime 24-38 1 5 20 22 18 8 3 1 0.125 0.5 0.016-2 0.25 1 ≤0.125-2
Meropenem 35-47 5 19 29 21 2 3 0.032 0.064 0.008-0.25 ≤0.25 ≤0.25 ≤0.25
Vancomycin 19-25 1 1 36 40 2 1 1 0.125-2 ≤0.5 ≤0.5 ≤0.5
Linezolid 27-35 5 10 35 28 1 2 0.25-2 1 1 ≤0.25-2
Rifampicin 34-46 5 11 27 26 5 1 1 0.008 0.016 <0.002-0.125 NR NR NR
* Susceptibility recommendation method: Medium: Mueller-Hinton (MH) plates with 5% defibrinated horse blood and 20 mg/L β-NAD (MH-F).
Inoculum:  McFarland  0.5.  Incubation:  5% CO2,  35±1  °C,  18±2h.  Isolates  with  insufficient  growth  after  16-20  h  incubation  were  re-incubated
immediately and inhibition zones and MICs read after a total of 40-44 h incubation. Reading: Read zone edges as the point showing no growth
viewed from the front of the plate with the lid removed and with reflected light.
For  the  wild-type  population  of  A.  urinae  isolates,  the  range  of  zone  diameters  differed  among  examined
antimicrobial  agents  from 6 mm (vancomycin)  to  14 mm (cefotaxime).  For  A.  sanguinicola,  wild-type populations
ranged from 5 mm (vancomycin) to 11 mm (meropenem).
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Table 2. MICs and zone diameters for A. sanguinicola isolates when tested by EUCAST standardized disk diffusion method,
Etest, and broth microdilution (Sensititre).
A. sanguinicola
Disk diffusion
(wildtype)
Etest Broth microdilution *
No. of isolates with MIC (mg/L) MIC (mg/L) MIC (mg/L)
Antibiotic mm <0.002 0.004 0.008 0.016 0.032 0.064 0.125 0.25 0.5 1 2 MIC50 MIC90 Range MIC50 MIC90 Range
Benzylpenicillin 25-34 1 15 20 2 0.064 0.064 0.016-0.125 ≤0.03 0.06 ≤0.03-0.06
Cefotaxime 24-34 1 11 12 11 3 0.25 0.5 0.064-1 0.25 1 ≤0.125-1
Meropenem 34-45 9 23 7 0.064 0.125 0.032-0.125 ≤0.25 ≤0.25 ≤0.25
Vancomycin 17-22 9 26 4 0.5 1 0.25-1 ≤0.5 ≤0.5 ≤0.5-1
Linezolid 27-35 10 25 4 1 2 0.5-2 1 1 ≤0.5-1
Rifampicin 28-35 1 2 12 18 5 0.064 0.125 0.008-0.125 NR NR NR
* Susceptibility recommendation method: Medium: Mueller-Hinton (MH) plates with 5% defibrinated horse blood and 20 mg/L β-NAD (MH-F).
Inoculum:  McFarland  0.5.  Incubation:  5% CO2,  35±1  °C,  18±2h.  Isolates  with  insufficient  growth  after  16-20  h  incubation  were  re-incubated
immediately and inhibition zones and MICs read after a total of 40-44 h incubation. Reading: Read zone edges as the point showing no growth
viewed from the front of the plate with the lid removed and with reflected light.
4. DISCUSSION
CLSI (August 2016) and EUCAST (January 2017) have currently established species-specific breakpoints for A.
urinae and A. sanguinicola and before the availability of such data, MICs needed to be interpreted using breakpoints
established for related bacteria as viridans group streptococci.
The  EUCAST  standardized  disk  diffusion  method  for  fastidious  microorganisms  uses  Mueller-Hinton  agar
supplemented with 5% defibrinated horse blood and 20 mg/L β-NAD (MH-F), and a standard inoculum of McFarland
0.5 for obtaining sufficient demarcating growth following 16-20 h incubation in ambient air supplemented with 5%
CO2.  In a study by Humphries & Hindler [9] they demonstrated good growth of 128 A. urinae  isolates when using
cation-adjusted Mueller-Hinton (MH) broth (CAMHB) supplemented with 2.5% to 5% lysed horse blood (LHB), which
is the CLSI recommended standard medium (CAMHB-LHB). In the present study, growth of A. urinae isolates were
weaker as compared to A. sanguinicola isolates and prolonged incubation were needed for 14 of the A. urinae isolates to
obtain readable growth.
In Table 3 the recommended MIC breakpoints by EUCAST and CLSI in addition to EUCAST recommended zone
diameter breakpoints are given for all of the examined antibiotics in this study. The EUCAST recommendations cover
A. urinae and A. sanguinicola and the CLSI recommendations additionally include Aerococcus viridans. The inhibition
zone diameters and MICs obtained were within CLSI and EUCAST recommendations for being susceptible, except for
one A. urinae strain using cefotaxime [15, 16].
Table 3. Recommendations given by EUCAST and CLSI for the six antibiotics examined in the present study.
Guideline EUCAST MIC breakpoint (mg/L)
EUCAST Zone diameter
breakpoint (mm) *
CLSI interpretive criteria MIC (mg/L) **
Antibiotic S ≤ R > S ≥ R < S ≤ I R ≥
Benzylpenicillin1 / penicillin2 0.125 0.125 21 21 0.12 0.25-2 4
Cefotaxime NR NR NR NR 1 2 4
Meropenem 0.25 0.25 31 31 0.5 NR NR
Vancomycin 1 1 16 16 1 NR NR
Linezolid NR NR NR NR 2 NR NR
Rifampicin 0.125 0.125 25 25 NR NR NR
S, Susceptible.
I, Intermediate.
R, Resistant.
NR, No recommendation.
1 Benzylpenicillin for EUCAST testing.
2 Penicillin for CLSI testing.
Quality control strain Streptococcus pneumoniae ATCC 49619 for both EUCAST and CLSI.
* Susceptibility recommendation method: Medium: Mueller-Hinton (MH) plates with 5% defibrinated horse blood and 20 mg/L β-NAD (MH-F).
Inoculum:  McFarland  0.5.  Incubation:  5% CO2,  35±1  °C,  18±2h.  Isolates  with  insufficient  growth  after  16-20  h  incubation  were  re-incubated
immediately and inhibition zones and MICs read after a total of 40-44 h incubation. Reading: Read zone edges as the point showing no growth
viewed from the front of the plate with the lid removed and with reflected light.
** Susceptibility recommendation method: Medium: Cation-adjusted Mueller-Hinton broth (CAMHB) supplemented with 2.5% lysed horse blood
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(CAMHB-LHB). Inoculum: Direct colony suspension, equivalent to a 0.5 McFarland standard. Incubation: 35 °C, 5% CO2, 20-24 h.
Broth microdilution and Etest MICs from this study corresponded to MIC values using BMD, agar dilution, and
gradient  tests  as  reported  in  a  review  from  Rasmussen  M  [1].  Rasmussen  M  [1]  summarized  published  antibiotic
susceptibility testing results of A. urinae and A. sanguinicola isolates using EUCAST breakpoints for viridans group
streptococci for 13 antibiotics for between 58 to 342 A. urinae isolates and between 8 to 65 A. sanguinicola isolates.
The antibiotic susceptibilities varied slightly between the two species. Both Aerococcus species were susceptible to β-
lactam antibiotics with modal MICs for penicillin based on 308 A. urinae and 65 A. sanguinicola isolates in the MIC
range of 0.03-0.06 mg/L [1].  In the present study, penicillin susceptibilities were in agreement with these findings.
Penicillin  MICs  for  A.  sanguinicola  isolates  were  in  general  one  dilution  higher  than  MICs  for  A.  urinae.  When
comparing  MICs  and  zone  diameters,  all  isolates  were  susceptible  using  the  EUCAST breakpoints.  The  MICs  for
cephalosporins, such as cefotaxime and ceftriaxone, have been reported close to the upper limit for susceptibility, but
still  often  within  the  range  of  being  susceptible,  using  the  CLSI  breakpoints  for  streptococci  [1].  In  the  study  of
Humphries & Hindler [9] which was based on 128 A. urinae  isolates,  all  but one isolate tested were susceptible to
meropenem (MIC ≤ 0.5 mg/L), with a modal MIC of ≤ 0.015 mg/L. The sole meropenem-nonsusceptible isolate was
also reproducibly reduced susceptible to ceftriaxone (4 mg/L) and cefotaxime (2 mg/L), but susceptible to penicillin
(0.06 mg/L). One of the A. urinae isolates in this study demonstrated an Etest MIC value one dilution above the CLSI
breakpoint  for  cefotaxime,  thereby  being  intermediate  susceptible,  but  zone  diameter  and  BMD  (Sensititre)  MIC
determinations  indicated  susceptibility.  For  meropenem,  MIC  ranges  were  observed  as  ≤  0.25  mg/L  for  both
Aerococcus  species.
Both species being capable of causing urinary tract infections, septicemia, and though seldom infective endocarditis
makes it favorable that isolates exhibited no resistance to penicillin. Two earlier studies have additionally indicated that
there is a synergistic killing effect when combining penicillin and an aminoglycoside [10, 20], though a new larger
study  could  only  demonstrate  such  synergy  in  a  minority  of  isolates  [2].  This  favorable  susceptibility  pattern  is
important as both organisms essentially are uropathogens, that may be resistant to more of the otherwise empirically
used  antibiotics  for  treating  urinary  tract  infections  (nalidixic  acid,  trimethoprim,  sulfonamides,  and  mecillinam),
though, the degree of resistance and methods for their detection are being debated [5, 7, 9].
Aerococci, as other Gram-positive cocci, except the inborn resistant pediococci, have modal MICs for vancomycin
of 1 mg/L or below. This has been reported for at least 308 isolates of A. urinae and 23 isolates of A. sanguinicola [1]
and makes vancomycin treatment of invasive infections as septicemia and infective endocarditis an attractive alternative
in the penicillin allergic patient, eventually in combination with gentamicin. Except for two A. urinae isolates (Etest
MIC 2 mg/L), results from the current study demonstrated vancomycin MICs for A. urinae and A. sanguinicola isolates
≤ 1 mg/L, which were in line with vancomycin MICs as reviewed by Rasmussen M [1] and susceptible according to
EUCAST and CLSI breakpoints.
Our isolates of both species were susceptible to linezolid using CLSI breakpoint and susceptible to rifampicin (Etest
testing  only)  using  EUCAST  breakpoints.  Humphries  &  Hindler  [9]  also  found  isolates  of  both  species  linezolid
susceptible, except two isolates with linezolid MICs of 4 and 8 mg/L. Sierra-Hoffman et al. [21, 22] examined 56 A.
urinae  isolates and Facklam et al.  [11] 15 isolates of A. sanguinicola  that were found susceptible to rifampicin, an
antibiotic with a possible role in combination antibiotic therapy in severe infective endocarditis cases.
Some limitations of the study are the number of strains that were included in the study and the limited geographic
distribution by the clinical strains only originating from Denmark, Switzerland, Spain, and the CCUG culture collection
of Gothenburg (Sweden). Not all of the clinical strains were having sufficient growth by following the EUCAST and
CLSI  recommended  incubation  conditions,  whereof  no  MIC  values  were  stated  for  some  of  the  strains.  Another
limitation by using a commercial BMD system is that only manufacturer selected antibiotic concentrations were tested
and a MIC reading at the lowest MIC concentration can only identify the lowest value without identification of an exact
MIC value. In a daily usage, the commercial BMD system is easy to use, reduces the hands-on time during preparation
of the plates and less time consuming.
CONCLUSION
In conclusion, A. urinae and A. sanguinicola are emerging pathogens, primarily uropathogens, but have also been
etiologic agents of bacteremia/septicemia and infective endocarditis; the latter though seldom well documented for A.
urinae. Suggestions on breakpoints for most relevant antibiotics were just recently released by CLSI and EUCAST. The
data obtained in this  study has been integrated as part  of  the background data for  the EUCAST clinical  breakpoint
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recommendations.
Data for six antimicrobial  agents using disk diffusion,  Etest,  and BMD were obtained for 120 A. urinae  and A.
sanguinicola isolates. MIC values obtained by Etest and BMD were in accordance within ± one dilution. All isolates
were found susceptible to the six antimicrobial agents of penicillin, cefotaxime, meropenem, vancomycin, linezolid, and
rifampicin.
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